Curvebeam Ai Ltd

Curvebeam Ai Ltd

CVB · AU · Healthcare / Medical Devices

0.018AUD+0.00 (0.00%)

Price History

Full chart

Market Stats

Previous Close0.018
Open0.017
Day Range0.017 – 0.018
52-Week Range0.016 – 0.13
Volume188.97K
Market Cap17.95M
P/E (TTM)0.00
Forward P/E0.00
EPS-0.04
Dividend Yield0.00%
Beta2.03
50-Day Avg0.0207
200-Day Avg0.0475

About

CurveBeam AI Limited engages in the development and manufacture of point-of care specialized weight bearing medical imaging equipment in Europe, North America, and internationally. The company offers HiRise for bilateral weight bearing CT imaging; LineUP, a bilateral, weight bearing CT imaging of the knees and lower extremities for orthpedic practices; pedCAT Premium and pedCAT for imaging of the foot and ankle; InReach, a point-of-care extremity CT imaging which assess the distal extremities with 3D clarity at a fraction of the dose; and CubeVue Software visualization tools. It also provides software CurveBeam AI Autometrics for automatically segment foot and ankle datasets; Axiometrics, provides a semi-automatic measurement of the axes of rotation of the hip, femur, knee, and ankle; and TALAS, a measurement tool that semi-automatically calculate hindfoot alignment based on reproducible three-dimensional anatomical landmarks. In addition, the company offers custom web-based cloud platform; and OSSView. The company was incorporated in 2009 and is headquartered in Hatfield, Pennsylvania.

Company Details

  • SectorHealthcare
  • IndustryMedical Devices
  • CEOMr. Gregory Wayne Brown BSc, MBA
  • Employees0
  • Headquarters2800 Bronze Drive, Hatfield, PA, United States, 19440, Australia
  • Websitehttps://curvebeamai.com

Leadership

  • Mr. Gregory Wayne Brown BSc, MBACEO, MD & Director · b. 1964
  • Mr. Ura Phillip Stephen AucklandCFO & Company Secretary
  • Mr. Arun Bahadur SinghCOO, CTO, President of US & Europe Division and Executive Director · b. 1959
  • Dr. Aloys MbalaCo-Founder
  • Mr. Ali GhasemzadehCo-Founder
  • Mr. S. Turner DeanChief Sales Officer
  • Ms. Vinti SinghVice President of Marketing
  • Dr. Yu Peng B.S., Ph.D.Chief Technology Officer (Artificial Intelligence) & Executive Director
  • Prof. Ego SeemanMedical Director - Endocrinology

Financials

Income Statement

Currency: AUD2021-06-302022-06-302023-06-302024-06-302025-06-30
Total Revenue7.20M1.67M8.06M6.53M12.10M
Growth (%)--76.77%+381.77%-18.97%+85.33%
Cost of Revenue3.98M3.43M3.66M3.52M6.67M
Gross Profit3.22M1.67M4.39M3.01M5.43M
Gross Margin44.76%100.00%54.54%46.08%44.89%
Operating Expense10.85M10.21M56.44M26.11M22.27M
Operating Income-7.62M-8.54M-52.05M-23.10M-16.84M
Operating Margin-105.92%-510.94%-646.15%-353.94%-139.24%
EBITDA--9.04M-43.52M-18.63M-
EBITDA Margin--540.73%-540.23%-285.40%-
Net Income-6.75M-8.54M-52.05M-23.10M-16.84M
Net Income Margin-93.73%-511.06%-646.15%-353.94%-139.24%
R&D--588.21K764.87K-
R&D as % of Total Revenue--7.30%11.72%-
Interest Expense560.00K2.66M13.90M1.29M205.57K
Interest Expense % of Total Revenue7.78%159.09%172.54%19.69%1.70%

Balance Sheet

Currency: AUD2021-06-302022-06-302023-06-302024-06-302025-06-30
Total Assets0061.36M63.33M60.98M
Total Liabilities00109.46M24.41M25.87M
Total Equity00-48.10M38.92M35.11M
Cash--5.16M6.45M-
Net Debt--8.56M8.64M-

Cash Flow

Currency: AUD2021-06-302022-06-302023-06-302024-06-302025-06-30
Operating Cash Flow--7.99M-21.67M-21.86M-11.17M
Investing Cash Flow--257.00K-4.10M-323.82K-489.18K
Financing Cash Flow4.52M16.52M22.25M23.63M10.31M
Capital Expenditure295.00K257.00K842.45K323.82K489.18K
Free Cash Flow-4.83M-10.50M-22.52M-22.18M-
FCF to OCF-131.40%103.89%101.48%-

Earnings

Report DateFeb 27, 2025Aug 27, 2025
EPS Estimate0.000.00
EPS Actual-0.03-0.02
Surprise--
Timing--

Key Statistics & Ratios

Market Cap17.95M
Enterprise Value39.05M
Trailing P/E0.00
Forward P/E0.00
Price / Sales2.07
Price / Book0.69
EPS-0.04
Book Value0.058
Revenue (TTM)8.67M
Gross Profit (TTM)2.81M
EBITDA-14.33M
Profit Margin-217.30%
Operating Margin-219.39%
Return on Equity-59.88%
Return on Assets-18.74%
Shares Outstanding854.90M
Shares Float266.32M
Beta2.03
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%